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A B S T R A C T
Development of rapid and multiplexed diagnostic tools is a top priority to address the current epidemic problem
of sexually transmitted diseases. Here we introduce a novel nanoplasmonic biosensor for simultaneous
detection of the two most common bacterial infections: Chlamydia trachomatis and Neisseria gonorrhoeae.
Our plasmonic microarray is composed of gold nanohole sensor arrays that exhibit the extraordinary optical
transmission (EOT), providing highly sensitive analysis in a label-free conﬁguration. The integration in a
microﬂuidic system and the precise immobilization of speciﬁc antibodies on the individual sensor arrays allow
for selective detection and quantiﬁcation of the bacteria in real-time. We achieved outstanding sensitivities for
direct immunoassay of urine samples, with a limit of detection of 300 colony forming units (CFU)/mL for C.
trachomatis and 1500 CFU/mL for N. gonorrhoeae. The multiplexing capability of our biosensor was
demonstrated by analyzing diﬀerent urine samples spiked with either C. trachomatis or N. gonorrhoeae, and
also containing both bacteria. We could successfully detect, identify and quantify the levels of the two bacteria in
a one-step assay, without the need for DNA extraction or ampliﬁcation techniques. This work opens up new
possibilities for the implementation of point-of-care biosensors that enable fast, simple and eﬃcient diagnosis of
sexually transmitted infections.
1. Introduction
Sexually transmitted infections (STI) are one of the most common
and widespread diseases around the world. Among them, infections
caused by Chlamydia trachomatis (CT) and Neisseria gonorrhoeae
(NG) stand out as the ﬁrst and second more reported bacterial
infections with nearly one million new cases each day (Newman
et al., 2015). Though they are easily curable, most of the infections
are asymptomatic and many individuals are not diagnosed and treated
in a timely manner, which can lead to long-term sequelae like
infertility, pelvic inﬂammatory disease, ectopic pregnancy or chronic
pelvic pain (Newman et al., 2015). Current standard techniques for CT
and NG detection rely on nucleic acid ampliﬁcation tests (NAATs),
which require laboratory settings and sample pretreatment procedures
(e.g. cell lysis, DNA extraction) (Gaydos and Hardick, 2014; Mark et al.,
2015; Papp et al., 2014). A rapid and simple detection of these
pathogenic infections will not only facilitate a prompt treatment but
also prevent onward transmission, help in risk awareness, reduce
economic expenses and signiﬁcantly promote health care in resource-
constrained environments.
Biosensors represent a unique opportunity to develop integrated
systems that enable fast and accurate STI diagnosis. In particular,
plasmonic technology oﬀers label-free quantiﬁcation, real-time analy-
sis, high sensitivity and an extraordinary potential for miniaturization
and integration in point-of-care devices (Brolo, 2012; Estevez et al.,
2014). However, despite the powerful sensor technology and the
progress made in integration, these next-generation biosensors still
need to overcome important challenges to be greeted in the clinical
ﬁeld. For plasmonic biosensors working in label-free conﬁguration,
main limitations are related to the ability to detect multiple biomarkers
simultaneously, with enough sensitivity, and directly in human ﬂuids
(Unser et al., 2015; Yoo and Lee, 2016). In the particular case of
bacteria detection, a fully integrated biosensor capable of performing
multiplexed and label-free detection at physiologically relevant con-
centrations has not been accomplished so far (Singh et al., 2014).
Signiﬁcant eﬀorts are directed to improve the assay sensitivity by
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performing sandwich immunoassays or employing magnetic beads for
signal enhancement. With this methodology, one can reach limits of
detection as low as 10–50 colony forming units (CFU)/mL (Sanvicens
et al., 2011; Wang et al., 2012) or even 3 CFU/mL (Torun et al., 2012),
but main drawbacks arise from the need of sample pretreatment or
post-ampliﬁcation steps. Others suggest the use of bacteriophages as
recognition elements for direct analysis, achieving high sensitivities
(101–103 CFU/mL) and also the possibility to evaluate antibiotic
resistance (Tawil et al., 2013). Regarding multiplexed detection, Yoo
et al. (2015) have developed a localized SPR sensor for high-through-
put and simultaneous detection of diﬀerent bacteria. Using aptamers as
biorecognition elements they reached limits of detection around
104 CFU/mL in standard buﬀer conditions, but no tests in biological
ﬂuids or real samples were performed.
In this article, we present a novel nanoplasmonic biosensor for
multiplexed detection of both C. trachomatis and N. gonorrhoeae
directly in urine samples. Our biosensor is based on the extraordinary
optical transmission (EOT) occurring in plasmonic nanohole arrays
(Rodrigo et al., 2016). This sensing principle enables not only label-free
and real-time detection but also the independent interrogation of each
nanohole array simultaneously, which facilitates the high-throughput
analysis in a simple manner. By selectively functionalizing the nano-
hole arrays with speciﬁc antibodies, we are able to capture and identify
the bacteria present in urine samples and provide a rapid diagnosis
without the need of cell lysis or DNA extraction. Furthermore, contrary
to the conventional SPR based on the Kretschmann prism-coupling
scheme, EOT can be achieved by normal light incidence and it is
compatible with the use of light emitting diodes (LEDs) and CMOS
(Complementary Metal Oxide Semiconductors) based imagers, allow-
ing exceptional miniaturization and a wide ﬁeld-of-view for multi-
plexing (Cetin et al., 2014; Chang et al., 2011). Therefore, the
methodology we describe here represents a signiﬁcant step forward
for the implementation of a biosensor that enables a rapid, simple and
eﬃcient STI diagnosis.
2. Materials and methods
2.1. Materials and bacteria culture
The list of reagents and materials used in this work and details of
nanofabrication, surface functionalization, and bacteria culture meth-
ods are provided in the Supplementary Information (SI).
2.2. Spectroscopic imaging and data processing
Plasmonic nanohole arrays (diameter 200 nm, period 600 nm) were
fabricated via a lift-oﬀ-free wafer-scale fabrication scheme based on
deep-UV lithography (details in the SI). For real-time biodetection
experiments, we utilize an inverted microscope (Nikon Eclipse-Ti) and
a CCD spectrometer (Andor Shamrock 303i). Brieﬂy, a broadband light
source illuminates the plasmonic microarray at normal incidence and
the transmitted light is delivered to the spectrometer through a 400 µm
width slit. For simultaneous analysis of 3 individual sensor arrays, we
employ a 4× Nikon objective lens (NA=0.13) embedded in the
microscope. The 3 sensors are aligned along the slit and each one is
spread as a single spectrum via the grating (600 l/mm) inside the
spectrometer. The wavelength range is adjusted to the EOT peak
position (~850 nm) and spectra images are then recorded on a
1024×1024 CCD camera (iKon-M934) at 0.5 s of exposure time.
Finally, the diﬀerent spectra are independently extracted and analyzed
with home-made MATLAB scripts to provide monitoring of the EOT
peak shifting. The peak position is determined by calculating the
centroid of the peak within a ﬁxed wavelength window (40% maximum
intensity) and plotted in real time. Sensorgrams show the centroid
shifting versus time of the 3 independent sensor areas simultaneously.
2.3. Bacteria detection experiments
The biofunctionalized plasmonic chip is assembled with the micro-
ﬂuidics (details in SI) and connected to a syringe pump with adjustable
pumping speed and a manually operated injection valve. Detection of
bacteria is performed by injection of 200 μL of the samples over the
biofunctionalized sensor surface at 20 μL/min ﬂow rate. A continuous
ﬂow of acetate buﬀer (pH 5) is kept during the analysis. Signal increase
was determined by extracting the diﬀerence in the mean of the centroid
values (n≥100 data points) before the analyte capture and after rinsing.
The antibody layer was regenerated (NaOH 20 mM) among measure-
ments for optimization purposes. The same antibody layer could be
used up to 10 detection cycles with a good reproducibility. Calibration
curves are obtained by measuring diﬀerent concentrations of bacteria
in triplicate. Mean and standard deviation are plotted and ﬁtted to a
linear regression model. Limit of detection (LOD) is calculated as the
concentration corresponding to the blank signal plus 3 times its
standard deviation, while the limit of quantiﬁcation (LOQ) is the
concentration corresponding to the blank signal plus 10 times its
standard deviation. Statistical analysis was performed as one-way
analysis of variance (ANOVA) followed by Bonferroni's Multiple
Comparison Test with statistical signiﬁcance threshold set at 0.05 (p
< 0.05). The data is analyzed using OriginPro 8.6 G software.
3. Results and discussion
3.1. Plasmonic nanohole array fabrication and microﬂuidics
integration
In our biosensor, we employ a plasmonic chip composed of nano-
hole arrays fabricated on free-standing silicon nitride membranes. To
create our plasmonic nanohole arrays we utilize a lift-oﬀ-free wafer-
scale fabrication scheme based on deep ultra-violet (UV) lithography
(Fig. 1a). Fabrication details are explained in the SI. Unlike the
fabrication of plasmonic chips using electron beam lithography that
requires sequential performance on each chip, our UV lithography-
based procedure can be carried out at wafer scale providing thousands
of plasmonic arrays with a high uniformity and reproducibility, and at
low cost. This is extremely important in order to minimize the cost of
the biosensor for an eventual implementation in point-of-care devices.
Besides, our fabrication method is highly ﬂexible so that plasmonic
chips with multiple designs, incorporating diﬀerent numbers of sensor
areas, sizes, and spatial arrangements, can be easily created. For this
work in particular, we employed a plasmonic microarray composed of 8
independent nanohole arrays (NHAs) separated with 1 mm distance
and in a 3×3 matrix form. Each NHA has an area of 100×100 µm, with
a hole diameter of 200 nm and 600 nm of array periodicity (Fig. 1b).
The optical sensitivity of the plasmonic nanohole arrays was previously
characterized achieving a bulk sensitivity around 600 nm/refractive
index unit (RIU) (Cetin et al., 2014).
We integrated the plasmonic chip into a multichannel microﬂuidics
system to facilitate sample delivery to the NHA sensor spots (Figs. 1c
and d). The microﬂuidics was fabricated as a double-layer polydi-
methylsiloxane (PDMS) device by soft lithography employing speciﬁ-
cally designed Si molds (details in the SI). The PDMS microﬂuidics
contained 3 independent channels of 15 nL volume each (60 µm
height, 500 µm width). Each channel included the 3 NHA sensors for
multiplexed detection (Fig. 2) and it can be used individually for the
analysis of diﬀerent samples. The microﬂuidic setup allows for the use
of low sample volumes and real-time monitoring of the bacteria
capture. Furthermore, it reduces the human contact with the sample
and simpliﬁes the whole biosensor performance making it easier to
operate.
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3.2. Multiplexed spectroscopic imaging in real time
For real-time and label-free biosensing, we utilize spectroscopic
imaging based on the extraordinary optical transmission (EOT)
phenomenon exhibited by the plasmonic nanohole arrays (Cetin
et al., 2014). This exceptional enhancement of the light transmission
is attributed to the grating coupling of an incident light with surface
plasmon (SP) resonances and it is characterized by the appearance of a
series of peaks and dips in the transmission spectrum. These SP modes
are highly sensitive to minute changes in the near-ﬁeld refractive index
of the nanoholes, so they can be exploited for biosensing spectroscopy.
When a biomolecular interaction takes place at the NHA surface, the
variation of the refractive index induces a spectral shift in the EOT peak
wavelength. Monitoring these spectral displacements enables the
extraction of quantitative bioanalytical information in real time and
in a label-free manner. The great sensing performance of our nano-
plasmonic biosensor has been previously demonstrated for the detec-
tion of proteins and infectious viruses from biological media (Coskun
et al., 2014; Yanik et al., 2010).
Fig. 2 shows a representative schematics of the biosensor platform
and illustrative graphs describing the working principle. We illuminate
the plasmonic microarray with a normally incident broadband light
source and collect the transmitted light from 3 in-line NHAs simulta-
neously (Fig. 2a). In the spectrometer, the acquired CCD image is
spread as individual spectra by using a medium grating (600 l/mm),
showing the three EOT peaks corresponding to the three NHAs. In
aqueous solution, the EOT peak appears at 850 nm wavelength
approximately (Fig. 2b). For measuring the peak displacements, we
implemented a series of MATLAB scripts based on the centroid
method. This data processing method consists in ﬁnding the center
of mass of the curve over a certain wavelength window (i.e. centroid)
and track it over time (Nenninger et al., 2002). We selected a
wavelength window corresponding to the 40% of the intensity, includ-
ing the maximum peak values plus the slopes. The slopes not only shift
as much as the peak, but also show highly stable shape helping to
reduce the spectral noise. Unlike using simple interrogation of the
maximum peak value, with the centroid method we can extraordinarily
minimize the noise coming from light instability or the spectrometer.
This allows us to enhance the signal-to-noise ratio and achieve lower
limits of detection. Furthermore, both centroid window determination
and tracking of the spectra shifts (i.e. sensorgrams) were achieved
using a user-friendly homemade interface, which allowed the real-time
visualization of the binding events (Fig. 2c).
3.3. Chlamydia and gonorrhea bacteria capture and quantiﬁcation
In order to detect the whole infectious bacteria directly from the
urine without any sample processing, we employed antibodies as
capturing probe. Even though immunoassays are presumably less
sensitive than nucleic acid-based assays (Gaydos and Hardick, 2014),
the later require a cell lysis pretreatment step that inevitably lengthens
the analysis time. We selected speciﬁc antibodies against the major
Fig. 1. Fabrication of plasmonic nanohole arrays and microﬂuidics integration: (a) Main fabrication steps of nanohole arrays on free-standing silicon nitride (SiN) membranes. (b)
Optical microscope images of the plasmonic chip layout acquired with 4x objective (top) and 20× objective (middle). SEM image of a nanohole array (bottom). (c) Schematics of the
microﬂuidics system. The top PDMS slab incorporates the 3 microﬂuidic channels with the inlet part, the sensor channels in contact with the plasmonic chip and the outlet part. The
bottom PDMS slab serves as chip holder and facilitates the binding to the top layer. (d) Picture of the gold plasmonic chip assembled with the PDMS microﬂuidics and the tubing for
sample delivery.
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outer membrane protein (MOMP) for both CT and NG bacteria. These
antibodies present high aﬃnity for the immunodominant antigen
exposed on the outer part of the bacteria cell membranes, so they
speciﬁcally recognize and capture the target specimen (Papp et al.,
2014). In order to maximize the sensitivity of the assay and ensure the
stability and robustness of the biorecognition layer, we applied a
functionalization strategy based on the protein A/G (Fig. 2d, details
in SI). The protein A/G is a recombinant protein that presents high
aﬃnity for the Fc region of the antibodies, capturing them in an
oriented manner and therefore guaranteeing available antigen binding
sites (Kausaite-Minkstimiene et al., 2010; Makaraviciute et al., 2015;
Mauriz et al., 2016; Sikkema, 1989). We immobilized the protein A/G
Fig. 2. Schematics of the nanoplasmonic biosensor working principle: (a) Cross-sectional overview of the biosensor set-up. (b) Representative graph illustrating the three EOT spectral
peaks acquired simultaneously from the three sensor arrays (transmission vs. wavelength). (c) Representative graph illustrating the multiplexed real-time monitoring of the EOT
wavelength shift (peak wavelength vs. time). (d) Schematics of the sensor surface biofunctionalization. The diﬀerent nanohole arrays are modiﬁed with diﬀerent antibodies: anti-
Neisseria gonorrhoeae (NG) (green), anti-Chlamydia trachomatis (CT) (blue) and a control antibody (red). Each microﬂuidic channel (black arrows) covers 3 in-line sensor arrays so it
includes the two speciﬁc sensors for the diﬀerent bacteria plus the negative control sensor. The zoom-in section illustrates the surface chemistry strategy employed for the sensors
functionalization.
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on the gold surface by covalently binding to a PEGylated self-assembled
monolayer (SAM), which provides an antifouling and stable coating.
For multiplexing purposes, antibody immobilization on the NHA was
carried out employing a high-precision microdispenser, which permits
the spotting of diﬀerent antibody solutions on the diﬀerent NHAs
(100×100 µm) using less than 1 nL of sample (Fig. S4 in SI). In order
to ensure the reliability and selectivity of our measurements, we
deﬁned one of the three in-line sensor arrays as our negative control
reference, using the other two arrays for the speciﬁc capture of CT and
NG respectively (Fig. 2d). We employed low concentrations of anti-
bodies (10 μg/mL) to generate a sparse layer, which may reduce steric
hindrance issues due to the big size of the bacteria. Finally, to get a
robust and stable antibody layer we added a crosslinker (bis(sulfosuc-
cinimidyl)suberate, BS3) which covalently binds the antibody to the
protein A/G. This step is critical to avoid desorption of antibodies from
the biosensor surface because of changes in the pH of the medium
(Soler et al., 2014).
To evaluate the sensitivity and speciﬁcity of our biosensor for
bacteria quantiﬁcation we ﬁrst focused on the detection of CT and NG
individually in standard buﬀer conditions. For optimization purposes,
in the laboratory we worked with puriﬁed and inactivated bacteria
(details in SI). We selected an inactivation procedure (i.e. 10%
formalin) that preserves the outer membrane structure of the bacteria
intact (Chao and Zhang, 2011), hence the capture with MOMP
antibodies is still possible and it is analogue to employing live bacteria
cells. Acetate buﬀer at pH=5 was selected as our standard buﬀer to
minimize electrostatic repulsion between the bacteria and our functio-
nalized surface (details in SI). We obtained both standard calibration
curves (Fig. 3) by introducing CT and NG spiked samples covering a
wide range of concentrations, from 10 to 107 CFU/mL (10-fold
dilution). Signals were collected from the NHA sensors previously
functionalized with anti-CT and anti-NG antibodies, respectively. We
observed increasing wavelength shifts in a concentration-dependent
manner (Fig. S6 in SI), directly correlated with the interaction between
the bacteria and its corresponding antibody. Furthermore, to demon-
strate the selectivity of our biosensor we also tested the possible
binding of the bacteria to the unspeciﬁc antibodies. We ﬂowed NG
samples over the anti-CT antibody, and vice versa (Fig. 3). Even when
using large concentrations of bacteria, nonspeciﬁc signals were negli-
gible. This corroborates that the wavelength shifts obtained for the
standard calibration curves exclusively came from speciﬁc capture of
the speciﬁc bacteria, verifying the accuracy of our label-free quantiﬁca-
tion. By ﬁtting the data to a linear regression model (R2(CT)=0.98,
R2(NG)=0.99) we could determine the Limit of Detection (LOD) and
Limit of Quantiﬁcation (LOQ) of our biosensor, deﬁned as the
concentration corresponding to the blank signal plus 3 times or 10
times its standard deviation, respectively (Eurachem, 1998). We
achieved a LOD of 400 CFU/mL for CT and 1000 CFU/mL for NG.
The limits of quantiﬁcation (LOQ) were found at 760 CFU/mL for CT
and 2800 CFU/mL for NG. These detection limits were considered
greatly satisfactory for diagnosis since they cover the physiological
concentration range found in the majority of the infection cases (Jaton
et al., 2006). Moreover, these results prove the high sensitivity of our
nanoplasmonic biosensor compared to the state-of-the-art technology.
The use of plasmonic biosensors for direct and label-free detection of
pathogenic microorganisms in human ﬂuids (e.g. SPR or localized SPR
platforms) has been limited so far by the low sensitivity of the assays,
usually reporting LODs in the range of 104 to 107 CFU/mL (Ahmed
et al., 2014; Huang et al., 2014; Tokel et al., 2015; Yoo and Lee, 2016).
With our biosensor, we reached more than 10 times lower detection
limit ( < 103 CFU/mL).
In addition, we evaluated the repeatability and accuracy of our
measurements by determining the inter-assay coeﬃcients of variation
(i.e. variability between assays performed with diﬀerent plasmonic
chips) for the quantiﬁcation of both bacteria (Table S1 in SI). The
values for the inter-assay CV were below 15% in all cases, which is the
maximum variability recommended for clinical analysis. This demon-
strates the reproducibility of the assay and proves the robustness of the
methodology. Finally, to further validate the bacteria capture on the
nanohole arrays we performed post-experiment SEM imaging of the
chips (Fig. S7 in SI). The images showed both speciﬁc bacteria captured
on the nanohole arrays, so we can conﬁrm that sensor responses came
from direct detection of the pathogens.
3.4. Direct detection of chlamydia and gonorrhea in urine
To validate the potential of our biosensor for its clinical application
we addressed the direct measurement in urine samples. This is
essential to oﬀer a fast diagnosis of STI that does not require any
sample pretreatment to be performed in clinical laboratories.
Moreover, the selection of urine as the biological sample permits a
simple and non-invasive analysis that could be eventually carried out at
diﬀerent points of care, such as doctor's oﬃce, planned parenthood
care centers or even directly by the user at home. One of the main
limitations for urine analysis is the extreme variability of the composi-
tion. Several parameters like the concentration of certain proteins vary
over a wide range between diﬀerent subjects, the diet or the collection
Fig. 3. Evaluation of the sensitivity and selectivity for the detection and quantiﬁcation of
both bacteria in buﬀer. (a) Standard calibration for speciﬁc detection of Chlamydia
trachomatis (CT) (blue). Signals are obtained by ﬂowing CT samples at diﬀerent
concentrations (101–107 CFU/mL) over a sensor array functionalized with anti-CT
antibody. Green triangles represent nonspeciﬁc binding of Neisseria gonorrhoeae (NG)
on the anti-CT antibody array. (b) Standard calibration for speciﬁc detection of NG
(green). Signals are obtained by ﬂowing NG samples at diﬀerent concentrations (101–
107 CFU/mL) over a sensor array functionalized with anti-NG antibody. Blue triangles
represent nonspeciﬁc binding of CT on the anti-NG antibody array. Each data point
represents the mean and standard deviation of three replicates. Data is ﬁtted to a linear
regression model.
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time (Rose et al., 2015). This variability in composition can result in a
higher or lower background that we should take into account when
extracting our speciﬁc signal (Soler et al., 2016). Therefore, the
presence of a control sensor in the same microﬂuidic channel becomes
indispensable to ensure the reliability of the assay. The multiplexing
design of our biosensor allows us to bring every single sample
simultaneously in contact with the sensor arrays functionalized with
diﬀerent antibodies, including a nonspeciﬁc common mouse antibody
that provides the negative control. Signals acquired from this control
sensor represent the background response corresponding to the
nonspeciﬁc adsorption of matrix components (e.g. proteins), thereby
providing a precise reference for the subtraction of the speciﬁc signal
(details in SI).
In this way, we obtained both calibration curves for the detection of
CT and NG in urine. Diﬀerent concentrations of CT and NG (from 10 to
107 CFU/mL) were spiked in negative urine samples and ﬂowed over
the functionalized NHAs. Urine was employed directly as obtained,
without performing any puriﬁcation or ﬁltration treatment. The sensor
response obtained from negative urine samples was considered our
blank signal in this case. Fig. 4 shows the detection curves for the two
bacteria when plotting the speciﬁc signal after subtracting the reference
background. We compared the obtained calibration curves in urine to
the standard calibration performed in buﬀer. As can be seen, the curves
for both conditions (i.e. urine and buﬀer) appear identical. This
conﬁrms that matrix components present in the urine do not inﬂuence
the bacteria capture and also that the sensor signal obtained after
reference subtraction solely comes from speciﬁc CT or NG detection.
Analytical sensitivity was also determined for measurements in urine
by calculating both limits of detection and quantiﬁcation. For CT
detection, the LOD was 300 CFU/mL and the LOQ was 590 CFU/mL.
For NG detection, the LOD was 150 CFU/mL and the LOQ was
3900 CFU/mL. These values are comparable to the ones obtained in
buﬀer conditions, therefore, validating the reliability of our methodol-
ogy.
3.5. Multiplexed analysis of chlamydia and gonorrhea in urine
samples
Finally, we proved the multiplexing capabilities of our nanoplas-
monic biosensor for simultaneous detection of both STI bacteria. The
microarray chip was functionalized with the three diﬀerent antibodies
(anti-CT, anti-NG and control) and assembled with the microﬂuidics in
such a way that each channel included the 3 diﬀerent sensors. Signals
were collected from the three individual NHAs at the same time. In a
ﬁrst experiment, we introduced a negative urine sample obtained from
a healthy donor (Fig. 5a). The exact same response was acquired from
the 3 independent sensor arrays. Since the healthy urine sample did
not contain any bacteria sample, we can attribute the response to the
nonspeciﬁc binding of protein components of the urine to the sensor
surface. This also conﬁrmed that the background signal is equivalent
for the 3 sensors, so the reference subtraction method is accurate. Next,
we introduced a urine sample spiked with CT at 107 CFU/mL (Fig. 5b).
We could observe a high positive signal coming from the anti-CT
functionalized sensor (blue line), while there is no cross-reactivity with
the anti-NG functionalized sensor (green line). In a third experiment,
we introduced a urine sample spiked with NG at the same concentra-
tion (107 CFU/mL) (Fig. 5c). In this case, the speciﬁc detection signal
only arises from the speciﬁc anti-NG functionalized sensor (green line),
with an insigniﬁcant cross-reactivity coming from the anti-CT functio-
nalized sensor (blue line). In addition, we performed a fourth experi-
ment by introducing a urine sample spiked with both CT and NG
bacteria at 107 CFU/mL (Fig. 5d). As we expected, the sensorgram
showed positive signals coming from both anti-CT and anti-NG
functionalized sensors but no signal in the negative control, which
remained at the background level. Statistical analysis conﬁrmed that
there were no signiﬁcant diﬀerences between the signals obtained when
measuring each bacteria sample separately (Figs. 5b and c) or both
bacteria coexisting in the same sample (Fig. 5d) (nCT=4, p > 0.05;
nNG=4, pNG > 0.05). Moreover, the signals measured in this multi-
plexed conﬁguration also matched with the signals obtained when
measuring each bacteria individually (Fig. 4). This demonstrates that
we were able to selectively capture, identify and quantify both CT and
NG simultaneously in a single urine sample.
We have demonstrated that our nanoplasmonic microarray allows
for multiplexed and label-free detection of STI bacteria with no cross-
reactivity. The proposed methodology has proved to be reliable and
accurate for the direct detection of whole-cell bacteria in urine samples,
without requiring any sample pretreatment or ampliﬁcation.
Furthermore, our technology is easily scalable to further include a
large number of sensor arrays for truly high-throughput analysis. In
this regard, on-going work is dedicated to the study and validation of
clinical samples and possible incorporation of other biomarkers that
ensure the diagnosis sensitivity and speciﬁcity. This, together with
integration in a handheld point-of-care device would permit a simple
identiﬁcation and diagnosis of STI in few minutes and using only a few
microliters of urine.
4. Conclusions
We have developed a novel nanoplasmonic biosensor for simulta-
Fig. 4. Quantiﬁcation of bacteria in urine and comparison to standard buﬀer samples.
(a) Standard calibration for CT in urine (solid line) and in buﬀer (dashed line). Signals
are obtained by ﬂowing urine or buﬀer samples spiked with diﬀerent concentrations of
CT over a sensor array functionalized with anti-CT antibody. (b) Standard calibration for
NG spiked in urine (solid line) and in buﬀer (dashed line). Signals are obtained by
ﬂowing urine or buﬀer samples spiked with diﬀerent concentrations of NG over a sensor
array functionalized with anti-NG antibody. Each data point represents the mean and
standard deviation of three replicates. Data is ﬁtted to a linear regression model.
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neous diagnosis of C. trachomatis and N. gonorrhoeae infections in
urine. Our plasmonic microarray based on gold nanohole sensors oﬀers
highly sensitive, label-free and multiplexed analysis in real time.
Microﬂuidic integration and a thorough optimization of surface
biofunctionalization provided a direct and fast quantiﬁcation of CT
and NG bacteria with excellent selectivity, accuracy and proved
reliability and robustness. We have achieved outstanding detection
sensitivities measuring directly in urine samples, without the need of
DNA extraction or post-ampliﬁcation steps. We have also demon-
strated the ability of our nanoplasmonic microarray for truly multi-
plexed detection of diﬀerent bacteria in a one-step assay. To our
knowledge, this is the ﬁrst report showing label-free and multiplexed
nanoplasmonic sensing of bacteria directly in biological samples and
within a physiologically relevant concentration without the need for
ampliﬁcation steps.
The work presented in this article represents a decisive and
necessary step towards the implementation of point-of-care diagnos-
tics. Our biosensor can be easily integrated into a portable handheld
device employing LED sources and CMOS detector, which signiﬁcantly
reduces the costs and enables the analysis performance outside the
clinical laboratory. Furthermore, the direct detection of the bacteria in
urine samples can provide a “while-you-wait” diagnosis of STI in a
noninvasive manner. This deﬁnitely signiﬁes a breakthrough in the
ﬁeld of sexually transmitted diseases, not only for diagnosis but for
transmission prevention and early treatment.
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Fig. 5. Multiplexed analysis of diﬀerent bacteria in urine. Sensorgrams show the signals corresponding to the three arrays functionalized with anti-CT antibody (blue), anti-NG antibody
(green) and the control antibody (red). Horizontal black line serves as reference to identify the urine background signal. (a) Background signal from negative a healthy urine sample. (b)
Speciﬁc detection of a CT spiked sample (107 CFU/mL) (blue line). (c) Speciﬁc detection of a NG spiked sample (107 CFU/mL) (green line). (d) Detection of both CT and NG spiked in
the same sample (107 CFU/mL each) (blue and green line).
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